Athersys gains on deal with Pfizer

Athersys Inc. (NASDAQ:ATHX) jumped $1.40 (140%) to $2.40 on Monday after granting Pfizer Inc. (NYSE:PFE) rights to develop and commercialize MultiStem to treat inflammatory bowel disease (IBD). The th...